Deer­field gives up rights to Windtree ther­a­py; Tra­vere inks deal with Re­nalys in Asia; Celu­lar­i­ty rais­es $21M

Plus, news about Prime Med­i­cine, Sagimet Bio­sciences and Adicet Bio:

Deer­field ter­mi­nates rights to 2017 deal with Windtree Ther­a­peu­tics: The biotech last year in-li­censed Aero­surf, the acute pul­monary drug/de­vice com­bi­na­tion at the cen­ter of the Deer­field deal. Back in Au­gust, Windtree said Lee’s Phar­ma­ceu­ti­cal will de­vel­op and com­mer­cial­ize a pair of Windtree’s acute pul­monary treat­ments, in­clud­ing Aero­surf. Deer­field no longer has rights to Aero­surf’s mile­stone pay­ments, and Windtree is hand­ing over about 600,000 shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER